These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 19884533)

  • 1. Androgen deprivation therapy and prostate cancer duration.
    Williams SG; Pickles T; Buyyounouski MK
    J Clin Oncol; 2009 Dec; 27(34):e228; author reply e229. PubMed ID: 19884533
    [No Abstract]   [Full Text] [Related]  

  • 2. The role of intermittent androgen deprivation in prostate cancer.
    Boccon-Gibod L; Hammerer P; Madersbacher S; Mottet N; Prayer-Galetti T; Tunn U
    BJU Int; 2007 Oct; 100(4):738-43. PubMed ID: 17662079
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate cancer--management of disseminated disease (intermittent androgen suppression).
    Lobel B; Richard F
    Acta Chir Iugosl; 2005; 52(4):11-2. PubMed ID: 16673586
    [No Abstract]   [Full Text] [Related]  

  • 4. Watchful waiting beats androgen deprivation therapy in early prostate cancer.
    Brower V
    J Natl Cancer Inst; 2008 Nov; 100(21):1494-6. PubMed ID: 18957680
    [No Abstract]   [Full Text] [Related]  

  • 5. [The question of intermittent hormonal treatment of cancer of the prostate].
    Boca P
    Acta Urol Belg; 1998 May; 66(2):17-20. PubMed ID: 9633121
    [No Abstract]   [Full Text] [Related]  

  • 6. [Intermittent androgen blockade in prostatic carcinoma].
    Vachalovský V; Dvorácek J
    Cas Lek Cesk; 2002 Oct; 141(21):669-72. PubMed ID: 12564373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long- or short-term hormones for locally advanced prostate cancer?
    Brower V
    J Natl Cancer Inst; 2009 Dec; 101(23):1606-8. PubMed ID: 19910554
    [No Abstract]   [Full Text] [Related]  

  • 8. [Histological investigation of prostate cancer treated with hormonal agents].
    Azumi M; Saga Y; Hashimoto H; Kakizaki H
    Hinyokika Kiyo; 2006 Oct; 52(10):781-4. PubMed ID: 17131867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent androgen deprivation therapy: conventional wisdom versus evidence.
    Tombal B
    Eur Urol; 2009 Jun; 55(6):1278-80. PubMed ID: 19303201
    [No Abstract]   [Full Text] [Related]  

  • 10. A review of the use of histrelin acetate in the treatment of prostate cancer.
    Crawford ED
    BJU Int; 2009 Mar; 103 Suppl 2():14-22. PubMed ID: 19228148
    [No Abstract]   [Full Text] [Related]  

  • 11. Androgen deprivation before prostate radiotherapy: how long is long enough?
    Parker C
    Lancet Oncol; 2011 May; 12(5):411-2. PubMed ID: 21440506
    [No Abstract]   [Full Text] [Related]  

  • 12. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Experience with therapy of prostate cancer in the Primorye Territory].
    Gurina LI; Iudin SV
    Vopr Onkol; 2004; 50(5):599-601. PubMed ID: 15715105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer.
    Gleave M; Klotz L; Taneja SS
    Urol Oncol; 2009; 27(1):81-6. PubMed ID: 19111804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is hormone ablation still the right choice for advanced prostate cancer?
    Fitzpatrick JM
    BJU Int; 2007 Jul; 100 Suppl 2():36-9. PubMed ID: 17594357
    [No Abstract]   [Full Text] [Related]  

  • 16. Competing risks for patients with localized prostate cancer.
    Seidenfeld J; Samson DJ; Albertsen PC
    J Natl Cancer Inst; 2007 Oct; 99(20):1498-9. PubMed ID: 17925533
    [No Abstract]   [Full Text] [Related]  

  • 17. Primary combined androgen blockade in localized disease and its mechanism.
    Namiki M; Kitagawa Y; Mizokami A; Koh E
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):303-15. PubMed ID: 18471788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent versus continuous androgen deprivation treatment of prostate cancer.
    Zhu J; Zheng Y
    J Clin Oncol; 2013 Nov; 31(31):4024. PubMed ID: 24062402
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
    Penson DF
    J Urol; 2016 Feb; 195(2):353. PubMed ID: 26852977
    [No Abstract]   [Full Text] [Related]  

  • 20. [Step up therapy].
    Shiono A; Kurokawa K; Ito K; Yamanaka H
    Nihon Rinsho; 2000 Jul; 58 Suppl():292-4. PubMed ID: 11022732
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.